JP2019116510A - Oral composition - Google Patents
Oral composition Download PDFInfo
- Publication number
- JP2019116510A JP2019116510A JP2019084502A JP2019084502A JP2019116510A JP 2019116510 A JP2019116510 A JP 2019116510A JP 2019084502 A JP2019084502 A JP 2019084502A JP 2019084502 A JP2019084502 A JP 2019084502A JP 2019116510 A JP2019116510 A JP 2019116510A
- Authority
- JP
- Japan
- Prior art keywords
- component
- weight
- parts
- composition
- oral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 64
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims abstract description 48
- 150000003839 salts Chemical class 0.000 claims abstract description 28
- 239000003945 anionic surfactant Substances 0.000 claims abstract description 24
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229960004889 salicylic acid Drugs 0.000 claims abstract description 20
- 210000000214 mouth Anatomy 0.000 claims description 50
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 claims description 38
- -1 sodium alkyl sulfate Chemical class 0.000 claims description 37
- 229960001047 methyl salicylate Drugs 0.000 claims description 19
- 239000011734 sodium Substances 0.000 claims description 15
- 229910052708 sodium Inorganic materials 0.000 claims description 15
- 239000000551 dentifrice Substances 0.000 claims description 13
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 claims description 10
- 108700004121 sarkosyl Proteins 0.000 claims description 10
- 125000002252 acyl group Chemical group 0.000 claims description 7
- 239000002324 mouth wash Substances 0.000 claims description 7
- 229940051866 mouthwash Drugs 0.000 claims description 5
- VAMXMNNIEUEQDV-UHFFFAOYSA-N methyl anthranilate Chemical compound COC(=O)C1=CC=CC=C1N VAMXMNNIEUEQDV-UHFFFAOYSA-N 0.000 claims description 4
- GYCKQBWUSACYIF-UHFFFAOYSA-N Ethyl salicylate Chemical compound CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 3
- 229940005667 ethyl salicylate Drugs 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 229940102398 methyl anthranilate Drugs 0.000 claims description 2
- PETRWTHZSKVLRE-UHFFFAOYSA-N 2-Methoxy-4-methylphenol Chemical compound COC1=CC(C)=CC=C1O PETRWTHZSKVLRE-UHFFFAOYSA-N 0.000 claims 2
- ZFMSMUAANRJZFM-UHFFFAOYSA-N Estragole Chemical compound COC1=CC=C(CC=C)C=C1 ZFMSMUAANRJZFM-UHFFFAOYSA-N 0.000 claims 2
- GEWDNTWNSAZUDX-WQMVXFAESA-N (-)-methyl jasmonate Chemical compound CC\C=C/C[C@@H]1[C@@H](CC(=O)OC)CCC1=O GEWDNTWNSAZUDX-WQMVXFAESA-N 0.000 claims 1
- MVOSYKNQRRHGKX-UHFFFAOYSA-N 11-Undecanolactone Chemical compound O=C1CCCCCCCCCCO1 MVOSYKNQRRHGKX-UHFFFAOYSA-N 0.000 claims 1
- BGTBFNDXYDYBEY-FNORWQNLSA-N 4-(2,6,6-Trimethylcyclohex-1-enyl)but-2-en-4-one Chemical compound C\C=C\C(=O)C1=C(C)CCCC1(C)C BGTBFNDXYDYBEY-FNORWQNLSA-N 0.000 claims 1
- POIARNZEYGURDG-FNORWQNLSA-N beta-damascenone Chemical compound C\C=C\C(=O)C1=C(C)C=CCC1(C)C POIARNZEYGURDG-FNORWQNLSA-N 0.000 claims 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims 1
- 229930002839 ionone Natural products 0.000 claims 1
- 150000002499 ionone derivatives Chemical class 0.000 claims 1
- GEWDNTWNSAZUDX-UHFFFAOYSA-N methyl 7-epi-jasmonate Natural products CCC=CCC1C(CC(=O)OC)CCC1=O GEWDNTWNSAZUDX-UHFFFAOYSA-N 0.000 claims 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims 1
- 229930007850 β-damascenone Natural products 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 abstract description 18
- 241000544270 Angelica acutiloba Species 0.000 abstract description 2
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract description 2
- 244000236658 Paeonia lactiflora Species 0.000 abstract description 2
- 239000002085 irritant Substances 0.000 abstract description 2
- 238000005187 foaming Methods 0.000 description 31
- 241000736199 Paeonia Species 0.000 description 20
- 235000006484 Paeonia officinalis Nutrition 0.000 description 20
- 229940024606 amino acid Drugs 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 17
- XOAAWQZATWQOTB-UHFFFAOYSA-N Taurine Natural products NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 15
- 229960003080 taurine Drugs 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 238000002156 mixing Methods 0.000 description 13
- 239000004094 surface-active agent Substances 0.000 description 12
- 239000000606 toothpaste Substances 0.000 description 12
- 229940034610 toothpaste Drugs 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 235000014113 dietary fatty acids Nutrition 0.000 description 10
- 239000000194 fatty acid Substances 0.000 description 10
- 229930195729 fatty acid Natural products 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 8
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 8
- 230000007794 irritation Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- 238000004140 cleaning Methods 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000006260 foam Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- KZRXPHCVIMWWDS-AWEZNQCLSA-N (4S)-4-amino-5-dodecanoyloxy-5-oxopentanoic acid Chemical compound CCCCCCCCCCCC(=O)OC(=O)[C@@H](N)CCC(O)=O KZRXPHCVIMWWDS-AWEZNQCLSA-N 0.000 description 4
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 4
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 229960000458 allantoin Drugs 0.000 description 4
- 229960003237 betaine Drugs 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- 238000013329 compounding Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 229940071085 lauroyl glutamate Drugs 0.000 description 4
- 210000002200 mouth mucosa Anatomy 0.000 description 4
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 3
- 235000011613 Pinus brutia Nutrition 0.000 description 3
- 241000018646 Pinus brutia Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 3
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000007872 degassing Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 229960002389 glycol salicylate Drugs 0.000 description 3
- 229960004949 glycyrrhizic acid Drugs 0.000 description 3
- 235000019410 glycyrrhizin Nutrition 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229940042585 tocopherol acetate Drugs 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- XHXUANMFYXWVNG-ADEWGFFLSA-N (-)-Menthyl acetate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(C)=O XHXUANMFYXWVNG-ADEWGFFLSA-N 0.000 description 2
- ULDHMXUKGWMISQ-SECBINFHSA-N (-)-carvone Chemical compound CC(=C)[C@@H]1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-SECBINFHSA-N 0.000 description 2
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 2
- GHBSPIPJMLAMEP-UHFFFAOYSA-N 6-pentyloxan-2-one Chemical compound CCCCCC1CCCC(=O)O1 GHBSPIPJMLAMEP-UHFFFAOYSA-N 0.000 description 2
- 241000208173 Apiaceae Species 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 239000002280 amphoteric surfactant Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 229940071124 cocoyl glutamate Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical group CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 239000004088 foaming agent Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- JARKCYVAAOWBJS-UHFFFAOYSA-N hexanal Chemical compound CCCCCC=O JARKCYVAAOWBJS-UHFFFAOYSA-N 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- MLFHJEHSLIIPHL-UHFFFAOYSA-N isoamyl acetate Chemical compound CC(C)CCOC(C)=O MLFHJEHSLIIPHL-UHFFFAOYSA-N 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- IFYYFLINQYPWGJ-UHFFFAOYSA-N n-hexyl-gamma-butyrolactone Natural products CCCCCCC1CCC(=O)O1 IFYYFLINQYPWGJ-UHFFFAOYSA-N 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- ZQBAKBUEJOMQEX-UHFFFAOYSA-N phenyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 ZQBAKBUEJOMQEX-UHFFFAOYSA-N 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 238000005498 polishing Methods 0.000 description 2
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229960001860 salicylate Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 229940045944 sodium lauroyl glutamate Drugs 0.000 description 2
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- IWIUXJGIDSGWDN-UQKRIMTDSA-M sodium;(2s)-2-(dodecanoylamino)pentanedioate;hydron Chemical compound [Na+].CCCCCCCCCCCC(=O)N[C@H](C([O-])=O)CCC(O)=O IWIUXJGIDSGWDN-UQKRIMTDSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- MBDOYVRWFFCFHM-SNAWJCMRSA-N (2E)-hexenal Chemical compound CCC\C=C\C=O MBDOYVRWFFCFHM-SNAWJCMRSA-N 0.000 description 1
- PDHSAQOQVUXZGQ-JKSUJKDBSA-N (2r,3s)-2-(3,4-dihydroxyphenyl)-3-methoxy-3,4-dihydro-2h-chromene-5,7-diol Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2OC)=CC=C(O)C(O)=C1 PDHSAQOQVUXZGQ-JKSUJKDBSA-N 0.000 description 1
- AVBJHQDHVYGQLS-AWEZNQCLSA-N (2s)-2-(dodecanoylamino)pentanedioic acid Chemical compound CCCCCCCCCCCC(=O)N[C@H](C(O)=O)CCC(O)=O AVBJHQDHVYGQLS-AWEZNQCLSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- JWVLBMIUAONEJT-ZSOSHZMMSA-N (4S)-4-amino-5-dodecanoyloxy-5-oxopentanoic acid ethanol Chemical compound CCO.CCO.CCO.CCCCCCCCCCCC(=O)OC(=O)[C@@H](N)CCC(O)=O JWVLBMIUAONEJT-ZSOSHZMMSA-N 0.000 description 1
- 239000001605 (5-methyl-2-propan-2-ylcyclohexyl) acetate Substances 0.000 description 1
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- NWGAAWUUGRXXSC-UHFFFAOYSA-N 1-(2-hydroxypropoxy)propan-2-yl 2-hydroxybenzoate Chemical compound CC(O)COCC(C)OC(=O)C1=CC=CC=C1O NWGAAWUUGRXXSC-UHFFFAOYSA-N 0.000 description 1
- HNAGHMKIPMKKBB-UHFFFAOYSA-N 1-benzylpyrrolidine-3-carboxamide Chemical compound C1C(C(=O)N)CCN1CC1=CC=CC=C1 HNAGHMKIPMKKBB-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- DORBKQIZZTWKOR-UHFFFAOYSA-N 2-(2-oxotridecylamino)ethanesulfonic acid;sodium Chemical compound [Na].CCCCCCCCCCCC(=O)CNCCS(O)(=O)=O DORBKQIZZTWKOR-UHFFFAOYSA-N 0.000 description 1
- XPALGXXLALUMLE-UHFFFAOYSA-N 2-(dimethylamino)tetradecanoic acid Chemical compound CCCCCCCCCCCCC(N(C)C)C(O)=O XPALGXXLALUMLE-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- GMGBBMQOXFAWRS-UHFFFAOYSA-N 2-[2,2-diaminoethyl(tetradecyl)amino]acetic acid Chemical compound CCCCCCCCCCCCCCN(CC(N)N)CC(O)=O GMGBBMQOXFAWRS-UHFFFAOYSA-N 0.000 description 1
- GNCOVOVCHIHPHP-UHFFFAOYSA-N 2-[[4-[4-[(1-anilino-1,3-dioxobutan-2-yl)diazenyl]-3-chlorophenyl]-2-chlorophenyl]diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC(C(=C1)Cl)=CC=C1C(C=C1Cl)=CC=C1N=NC(C(C)=O)C(=O)NC1=CC=CC=C1 GNCOVOVCHIHPHP-UHFFFAOYSA-N 0.000 description 1
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- DABQDIXIAXPQFG-UHFFFAOYSA-N 2-[dodecanoyl(methyl)amino]ethanesulfonic acid Chemical compound CCCCCCCCCCCC(=O)N(C)CCS(O)(=O)=O DABQDIXIAXPQFG-UHFFFAOYSA-N 0.000 description 1
- NGOZDSMNMIRDFP-UHFFFAOYSA-N 2-[methyl(tetradecanoyl)amino]acetic acid Chemical compound CCCCCCCCCCCCCC(=O)N(C)CC(O)=O NGOZDSMNMIRDFP-UHFFFAOYSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- DMBTYPPQYTYHFZ-UHFFFAOYSA-N 2-hydroxybenzoic acid methyl 2-hydroxybenzoate Chemical compound OC(=O)C1=CC=CC=C1O.COC(=O)C1=CC=CC=C1O DMBTYPPQYTYHFZ-UHFFFAOYSA-N 0.000 description 1
- UBVSIAHUTXHQTD-UHFFFAOYSA-N 2-n-(4-bromophenyl)-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(NC=2C=CC(Br)=CC=2)=N1 UBVSIAHUTXHQTD-UHFFFAOYSA-N 0.000 description 1
- UNWFFCPRJXMCNV-UHFFFAOYSA-N 3-[dodecanoyl(methyl)amino]propanoic acid Chemical compound CCCCCCCCCCCC(=O)N(C)CCC(O)=O UNWFFCPRJXMCNV-UHFFFAOYSA-N 0.000 description 1
- NBDYSLCMCUDINP-UHFFFAOYSA-N 3-[dodecanoyl(methyl)amino]propanoic acid;sodium Chemical compound [Na].CCCCCCCCCCCC(=O)N(C)CCC(O)=O NBDYSLCMCUDINP-UHFFFAOYSA-N 0.000 description 1
- KFYGELIIGMESGJ-UHFFFAOYSA-N 3-aminopropanoic acid;sodium Chemical compound [Na].NCCC(O)=O KFYGELIIGMESGJ-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- AXCXHFKZHDEKTP-NSCUHMNNSA-N 4-methoxycinnamaldehyde Chemical compound COC1=CC=C(\C=C\C=O)C=C1 AXCXHFKZHDEKTP-NSCUHMNNSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- WLDHEUZGFKACJH-ZRUFZDNISA-K Amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1\N=N\C1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-ZRUFZDNISA-K 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 235000007558 Avena sp Nutrition 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 240000007154 Coffea arabica Species 0.000 description 1
- 235000002787 Coriandrum sativum Nutrition 0.000 description 1
- 244000018436 Coriandrum sativum Species 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 240000001980 Cucurbita pepo Species 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- XHXUANMFYXWVNG-UHFFFAOYSA-N D-menthyl acetate Natural products CC(C)C1CCC(C)CC1OC(C)=O XHXUANMFYXWVNG-UHFFFAOYSA-N 0.000 description 1
- 108010001682 Dextranase Proteins 0.000 description 1
- 240000002943 Elettaria cardamomum Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- YIKYNHJUKRTCJL-UHFFFAOYSA-N Ethyl maltol Chemical compound CCC=1OC=CC(=O)C=1O YIKYNHJUKRTCJL-UHFFFAOYSA-N 0.000 description 1
- VUNOFAIHSALQQH-UHFFFAOYSA-N Ethyl menthane carboxamide Chemical compound CCNC(=O)C1CC(C)CCC1C(C)C VUNOFAIHSALQQH-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 241000147041 Guaiacum officinale Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-O Imidazolium Chemical compound C1=C[NH+]=CN1 RAXXELZNTBOGNW-UHFFFAOYSA-O 0.000 description 1
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- MQHWFIOJQSCFNM-UHFFFAOYSA-L Magnesium salicylate Chemical compound [Mg+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O MQHWFIOJQSCFNM-UHFFFAOYSA-L 0.000 description 1
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N N-methylaminoacetic acid Natural products C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 235000011203 Origanum Nutrition 0.000 description 1
- 240000000783 Origanum majorana Species 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 241001474977 Palla Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- LQKRYVGRPXFFAV-UHFFFAOYSA-N Phenylmethylglycidic ester Chemical compound CCOC(=O)C1OC1(C)C1=CC=CC=C1 LQKRYVGRPXFFAV-UHFFFAOYSA-N 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 229930184148 Spiranthol Natural products 0.000 description 1
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FHNINJWBTRXEBC-UHFFFAOYSA-N Sudan III Chemical compound OC1=CC=C2C=CC=CC2=C1N=NC(C=C1)=CC=C1N=NC1=CC=CC=C1 FHNINJWBTRXEBC-UHFFFAOYSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 description 1
- 208000012931 Urologic disease Diseases 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- UJNOLBSYLSYIBM-WISYIIOYSA-N [(1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl] (2r)-2-hydroxypropanoate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)[C@@H](C)O UJNOLBSYLSYIBM-WISYIIOYSA-N 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- OYCUCVYCOQBTLP-UHFFFAOYSA-J [Ti+4].[O-]C(=O)c1ccccc1[O-].[O-]C(=O)c1ccccc1[O-] Chemical compound [Ti+4].[O-]C(=O)c1ccccc1[O-].[O-]C(=O)c1ccccc1[O-] OYCUCVYCOQBTLP-UHFFFAOYSA-J 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940011037 anethole Drugs 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- 235000013532 brandy Nutrition 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940043256 calcium pyrophosphate Drugs 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- AVVIDTZRJBSXML-UHFFFAOYSA-L calcium;2-carboxyphenolate;dihydrate Chemical compound O.O.[Ca+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O AVVIDTZRJBSXML-UHFFFAOYSA-L 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 235000005300 cardamomo Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Natural products CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 229940124579 cold medicine Drugs 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- QGGZBXOADPVUPN-UHFFFAOYSA-N dihydrochalcone Chemical compound C=1C=CC=CC=1C(=O)CCC1=CC=CC=C1 QGGZBXOADPVUPN-UHFFFAOYSA-N 0.000 description 1
- PXLWOFBAEVGBOA-UHFFFAOYSA-N dihydrochalcone Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=CC(C(=O)CC(O)C=2C=CC(O)=CC=2)=C1O PXLWOFBAEVGBOA-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 1
- DDXLVDQZPFLQMZ-UHFFFAOYSA-M dodecyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)C DDXLVDQZPFLQMZ-UHFFFAOYSA-M 0.000 description 1
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000012732 erythrosine Nutrition 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 229940093503 ethyl maltol Drugs 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229940073505 ethyl vanillin Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 108010000165 exo-1,3-alpha-glucanase Proteins 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- IFYYFLINQYPWGJ-VIFPVBQESA-N gamma-Decalactone Natural products CCCCCC[C@H]1CCC(=O)O1 IFYYFLINQYPWGJ-VIFPVBQESA-N 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940127227 gastrointestinal drug Drugs 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 229960001269 glycine hydrochloride Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940091561 guaiac Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 229940117955 isoamyl acetate Drugs 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229940043353 maltol Drugs 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- 229930007503 menthone Natural products 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 239000001627 myristica fragrans houtt. fruit oil Substances 0.000 description 1
- 229940070800 myristoyl glutamate Drugs 0.000 description 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- AXCXHFKZHDEKTP-UHFFFAOYSA-N para-methoxycinnamaldehyde Natural products COC1=CC=C(C=CC=O)C=C1 AXCXHFKZHDEKTP-UHFFFAOYSA-N 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 229960000969 phenyl salicylate Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- FRMWBRPWYBNAFB-UHFFFAOYSA-M potassium salicylate Chemical compound [K+].OC1=CC=CC=C1C([O-])=O FRMWBRPWYBNAFB-UHFFFAOYSA-M 0.000 description 1
- 229960003629 potassium salicylate Drugs 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- XIBUKSQTWSKJMQ-QTNFYWBSSA-M potassium;(4s)-4-amino-5-hydroxy-5-oxopentanoate;hydrate Chemical compound O.[K+].[O-]C(=O)[C@@H](N)CCC(O)=O XIBUKSQTWSKJMQ-QTNFYWBSSA-M 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 239000010668 rosemary oil Substances 0.000 description 1
- 229940058206 rosemary oil Drugs 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 239000010670 sage oil Substances 0.000 description 1
- 229960000581 salicylamide Drugs 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 229940057950 sodium laureth sulfate Drugs 0.000 description 1
- AQMNWCRSESPIJM-UHFFFAOYSA-M sodium metaphosphate Chemical compound [Na+].[O-]P(=O)=O AQMNWCRSESPIJM-UHFFFAOYSA-M 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- BVMJGZKBXAVKJN-UQKRIMTDSA-M sodium;(4s)-4-amino-5-dodecanoyloxy-5-oxopentanoate Chemical compound [Na+].CCCCCCCCCCCC(=O)OC(=O)[C@@H](N)CCC([O-])=O BVMJGZKBXAVKJN-UQKRIMTDSA-M 0.000 description 1
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000020354 squash Nutrition 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229910001631 strontium chloride Inorganic materials 0.000 description 1
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 229940119463 sunflower seed extract Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 239000010678 thyme oil Substances 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- VXYADVIJALMOEQ-UHFFFAOYSA-K tris(lactato)aluminium Chemical compound CC(O)C(=O)O[Al](OC(=O)C(C)O)OC(=O)C(C)O VXYADVIJALMOEQ-UHFFFAOYSA-K 0.000 description 1
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 1
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 239000011746 zinc citrate Substances 0.000 description 1
- 235000006076 zinc citrate Nutrition 0.000 description 1
- 229940068475 zinc citrate Drugs 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- GFQYVLUOOAAOGM-UHFFFAOYSA-N zirconium(iv) silicate Chemical compound [Zr+4].[O-][Si]([O-])([O-])[O-] GFQYVLUOOAAOGM-UHFFFAOYSA-N 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
本発明は、低刺激性であり、且つ起泡性の高い口腔用組成物に関する。 The present invention relates to an oral composition which is hypoallergenic and highly foamable.
歯磨剤、洗口剤等の口腔用組成物には、通常、洗浄力を高め、更に口腔内での起泡によって使用者に心地よい使用感や清掃感を与える目的で界面活性剤が配合されている。このような口腔用組成物に用いられる界面活性剤は、口腔粘膜に適用されることから高い安全性が求められる。口腔内に対する安全性を満たし、高い発泡性を発揮することができ、且つ比較的安価であるラウリル硫酸ナトリウム、ラウレス硫酸ナトリウム等のアニオン界面活性剤が従来使用されている。 In oral compositions such as dentifrices and mouthrinses, a surfactant is usually incorporated for the purpose of enhancing the detergency and further giving the user a pleasant feeling of use and a feeling of cleaning by foaming in the oral cavity. There is. The surfactant used in such an oral composition is required to have high safety because it is applied to the oral mucosa. An anionic surfactant such as sodium lauryl sulfate or sodium laureth sulfate, which can satisfy the safety for the oral cavity, can exhibit high foaming property, and is relatively inexpensive, is conventionally used.
また、口腔用組成物の起泡性を高めて口腔内での泡立ちをよくし、満足のいく使用感や清掃感を実現するためには、前述のアニオン界面活性剤を多く配合する処方が組まれるのが一般的である。しかし、アニオン界面活性剤を多く配合することは、アニオン界面活性剤による口腔粘膜への刺激が増強され、特に口内乾燥症(ドライマウス)や知覚過敏に悩む患者は、不快感や強い刺激を感じるため、敬遠される傾向が強い。そのため、界面活性剤として刺激の少ない非イオン性界面活性剤のみを含む口腔用組成物も提供されるが(例えば特許文献1を参照)、価格が高い割に消費者を満足させるだけの起泡性や洗浄作用を発揮させることが困難であった。 In addition, in order to enhance the foamability of the composition for oral cavity to improve foaming in the oral cavity and to achieve a satisfactory feeling of use and a feeling of cleaning, a formulation including a large amount of the above-mentioned anionic surfactant is assembled. It is common to However, the combination of a large amount of anionic surfactant enhances the stimulation of the oral mucosa by the anionic surfactant, and in particular, patients suffering from dry mouth and hypersensitivity feel discomfort and strong irritation. Therefore, they tend to be avoided. Therefore, although an oral composition containing only a non-irritant nonionic surfactant as a surfactant is also provided (see, for example, Patent Document 1), foaming is sufficient to satisfy consumers for a high price. It was difficult to exert the nature and the cleaning action.
低刺激性の界面活性剤として他に、ラウロイルメチルタウリン、ラウロイルサルコシン等のアミノ酸系アニオン界面活性剤も知られている。しかし、これらの界面活性剤もラウリル硫酸ナトリウム等の従来一般的に使用されている界面活性剤に比べると起泡性に劣り、使用者が満足するような発泡が得られるものではなかった。このような背景から、口腔内への刺激が低減され、且つ十分な起泡性を有する口腔用組成物が求められていた。 In addition, amino acid based anionic surfactants such as lauroyl methyl taurine and lauroyl sarcosine are also known as mild surfactants. However, these surfactants are also inferior in foamability to conventionally used surfactants such as sodium lauryl sulfate, and foams which satisfy the user were not obtained. From such a background, there has been a demand for an oral composition having reduced irritation to the oral cavity and having sufficient foamability.
本発明は、低刺激性であり、優れた起泡性を有する口腔用組成物を提供することを主な課題とする。 An object of the present invention is to provide an oral composition which is mild and has excellent foamability.
本発明者らは、上記課題を解決すべく鋭意検討を行った結果、アミノ酸系アニオン界面活性剤と、トウキ、シャクヤク、サリチル酸メチルとを所定の割合で組合せて配合することにより、口内に適用した際の刺激が低減されながらも十分な起泡力を備えた口腔用組成物が得られることを見出した。本発明はこれらの知見に基づいて更に研究を重ねた結果完成されたものである。 As a result of intensive studies to solve the above problems, the present inventors applied the compound to the mouth by combining and combining an amino acid based anionic surfactant, touki, peony and methyl salicylate in a predetermined ratio. It has been found that an oral composition having sufficient foaming power can be obtained while the irritation during the treatment is reduced. The present invention has been completed as a result of further studies based on these findings.
即ち、本発明は下記態様の口腔用組成物を提供する。
項1.(A)アミノ酸系アニオン界面活性剤、及び
(B)トウキ、シャクヤク、サリチル酸、サリチル酸の誘導体及びサリチル酸の塩からなる群より選択される少なくとも1種
を含み、且つ前記(A)成分100重量部に対する前記(B)成分の含有量が0.1〜500重量部である、口腔用組成物。
項2.前記(A)成分100重量部に対する前記(B)成分の含有量が2〜200重量部である、項1に記載される口腔用組成物。
項3.前記アミノ酸系アニオン界面活性剤が、炭素数8〜18の飽和又は不飽和のアシル基を有する項1又は2に記載される口腔用組成物。
項4.口腔用組成物中に含まれるアニオン界面活性剤の総重量に対する前記アミノ酸系アニオン界面活性剤の割合が50重量%以上である、項1〜3のいずれかに記載される口腔用組成物。
項5.前記(A)成分が、ラウロイルメチルタウリン、ラウロイルメチルタウリンの塩、ラウロイルグルタミン酸、ラウロイルグルタミン酸の塩、ラウロイルサルコシン、及びラウロイルサルコシンの塩からなる群より選択される少なくとも1種である、項1〜4のいずれかに記載される口腔用組成物。
項6.前記(A)成分がラウロイルメチルタウリン及び/又はその塩である、項1〜5のいずれかに記載される口腔用組成物。
項7.歯磨剤又は洗口剤である、項1〜6のいずれかに記載される口腔用組成物。
That is, the present invention provides the composition for oral cavity of the following aspect.
Item 1. (A) An amino acid type anionic surfactant, and (B) at least one selected from the group consisting of a touki, a peony, salicylic acid, a derivative of salicylic acid and a salt of salicylic acid, and based on 100 parts by weight of the component (A) The composition for oral cavity whose content of the said (B) component is 0.1-500 weight part.
Item 2. The composition for oral cavity described in Item 1, wherein the content of the component (B) is 2 to 200 parts by weight with respect to 100 parts by weight of the component (A).
Item 3. The composition for oral cavity as described in said claim | item 1 or 2 in which the said amino acid type | system | group anionic surfactant has a C8-C18 saturated or unsaturated acyl group.
Item 4. The composition for oral cavity as described in any one of Items 1 to 3, wherein the ratio of the amino acid based anionic surfactant to the total weight of the anionic surfactant contained in the composition for oral cavity is 50% by weight or more.
Item 5. The component (A) is at least one selected from the group consisting of lauroyl methyl taurine, a salt of lauroyl methyl taurine, lauroyl glutamate, a salt of lauroyl glutamate, lauroyl sarcosine, and a salt of lauroyl sarcosine, The composition for oral cavity described in any of the above.
Item 6. The oral composition according to any one of Items 1 to 5, wherein the component (A) is lauroyl methyl taurine and / or a salt thereof.
Item 7. 7. The composition for oral cavity described in any one of Items 1 to 6, which is a dentifrice or a mouthwash.
本発明の口腔用組成物によれば、口腔に適用した際の刺激や痛みが低減され、且つ口腔用組成物として十分な泡立ちを実現することができる。従って、本発明によれば、優れた使用感や実用性を備えた口腔用組成物を提供することができる。 According to the composition for oral cavity of the present invention, irritation and pain when applied to the oral cavity can be reduced, and sufficient foaming can be realized as a composition for oral cavity. Therefore, according to the present invention, it is possible to provide an oral composition having excellent feeling in use and practicality.
1.口腔用組成物
本発明の口腔用組成物は(A)アミノ酸系アニオン界面活性剤と、(B)トウキ、シャクヤク、サリチル酸、サリチル酸の誘導体及びサリチル酸の塩からなる群より選択される少なくとも1種とを含み、且つ、前記(A)成分100重量部に対する前記(B)成分の含有量が0.1〜500重量部であることを特徴とする。以下、本発明の口腔用組成物について詳述する。
1. Composition for oral cavity The composition for oral cavity of the present invention is at least one selected from the group consisting of (A) an amino acid based anionic surfactant, (B) touki, peony, salicylic acid, derivatives of salicylic acid and salts of salicylic acid. And a seed, and the content of the component (B) is 0.1 to 500 parts by weight with respect to 100 parts by weight of the component (A). Hereinafter, the composition for oral cavity of this invention is explained in full detail.
(A)成分
本発明の口腔用組成物の(A)成分であるアミノ酸系アニオン界面活性剤は、公知のものから適宜選択して使用することができるが、例えば炭素数8〜18、好ましくは炭素数10〜16、より好ましくは10〜14、更に好ましくは12〜14の飽和又は不飽和のアシル基を有するアミノ酸又はタウリンが例示される。アシル基は、アミノ酸又はタウリンのアミノ基と、カルボキシル基とが結合することにより形成される。ここで、アシル基としては、具体的にはオクチル基、デシル基、ラウロイル基、ミリストイル基、パルミトイル基、ステアリル基等が例示される。
(A) Component The amino acid-based anionic surfactant which is the component (A) of the composition for oral cavity of the present invention can be appropriately selected from known ones and used, for example, having 8 to 18 carbon atoms, preferably Examples are amino acids or taurines having a saturated or unsaturated acyl group having a carbon number of 10 to 16, more preferably 10 to 14, and further preferably 12 to 14. The acyl group is formed by combining an amino group of an amino acid or taurine with a carboxyl group. Here, specific examples of the acyl group include octyl group, decyl group, lauroyl group, myristoyl group, palmitoyl group, stearyl group and the like.
また、本発明のアミノ酸系界面活性剤は、塩の形態で使用されてもよく、例えば、ナトリウム、カリウム等のアルカリ金属塩;マグネシウム等のアルカリ土類金属塩;モノエタノールアミン、トリエタノールアミン等の有機アミン塩が挙げられる。 In addition, the amino acid surfactant of the present invention may be used in the form of a salt, for example, alkali metal salts such as sodium and potassium; alkaline earth metal salts such as magnesium; monoethanolamine, triethanolamine and the like And organic amine salts of
本発明の(A)成分として具体的には、ラウロイルサルコシン、ラウロイルサルコシンナトリウム、ミリストイルサルコシントリエタノールアミンなどのアシルサルコシン及びその塩;ラウロイルメチル−β−アラニン、ラウロイルメチル−β−アラニンナトリウム、パルミトイルメチル−β−アラニンナトリウムなどのアシルアラニン及びその塩;ラウロイルメチルタウリン、ラウロイルメチルタウリンナトリウム、ココイルメチルタウリンナトリウム、パルミトイルメチルタウリン、パルミトイルメチルタウリンナトリウムなどのアシルタウリン及びその塩;ミリストイルグルタミン酸ナトリウム、ココイルグルタミン酸カリウム、ラウロイルグルタミン酸、ラウロイルグルタミン酸ナトリウム、ラウロイルグルタミン酸トリエタノールアミンなどのアシルグルタミン酸及びその塩;ミリストイルグルタミン、ココイルグルタミン、ラウロイルグルタミンなどのアシルグルタミン等が例示される。これらの中でも、口内に適用する場合の安全性が確認されており、且つ口腔粘膜に対する刺激性がより低いという観点から、ラウロイルメチルタウリン又はその塩、ラウロイルグルタミン酸又はその塩、ラウロイルサルコシン又はその塩が好ましく、ラウロイルメチルタウリン又はその塩が、更に好ましいものとして挙げられる。これらはその1種を単独で用いても2種以上を併用してもよい。 Specific examples of the component (A) of the present invention include acyl sarcosine and its salts such as lauroyl sarcosine, sodium lauroyl sarcosine and myristoyl sarcosine triethanolamine; lauroyl methyl-β-alanine, lauroyl methyl-β-alanine sodium, palmitoyl methyl Acylalanine such as β-alanine sodium and salts thereof; lauroyl methyltaurine, lauroylmethyltaurine sodium, sodium cocoylmethyltaurine, palmitoylmethyltaurine, palmitoylmethyltaurine sodium and other acyltaurines and salts thereof; myristoyl sodium glutamate, cocoyl glutamate potassium , Lauroyl glutamate, sodium lauroyl glutamate, lauroyl glutamate triethanolate Acyl glutamic acid and its salts such emissions; myristoyl glutamate, cocoyl glutamate, acyl glutamic like such as lauroyl glutamate are exemplified. Among these, lauroyl methyl taurine or a salt thereof, lauroyl glutamic acid or a salt thereof, lauroyl sarcosine or a salt thereof, or the like from the viewpoint of safety when applied to the mouth and lower irritation to the oral mucosa. Preferably, lauroyl methyl taurine or a salt thereof is mentioned as a further preferred one. One of these may be used alone, or two or more may be used in combination.
ラウロイルメチルタウリンナトリウムについては、例えば、日光ケミカルズ株式会社等から商業的に入手可能である。ラウロイルグルタミン酸ナトリウムについては、例えば、味の素株式会社等から商業的に入手可能である。ラウロイルサルコシンナトリウムについては、例えば、日光ケミカルズ株式会社、川研ファインケミカル株式会社、クローダジャパン株式会社等から商業的に入手可能である。 About lauroyl methyl taurine sodium, it is commercially available from Nikko Chemicals Co., Ltd. etc., for example. Lauroyl glutamate sodium is commercially available, for example, from Ajinomoto Co., Ltd. Lauroyl sarcosine sodium is commercially available, for example, from Nikko Chemicals Co., Ltd., Kawaken Fine Chemical Co., Ltd., Croda Japan Co., Ltd., and the like.
本発明の口腔用組成物中の(A)成分の含有量は、組成物の総量に対して0.3〜2.5重量%、好ましくは0.5〜2重量%、より好ましくは0.5〜1.5重量%、更に好ましくは0.5〜1.0重量%が挙げられる。 The content of the component (A) in the composition for oral cavity of the present invention is 0.3 to 2.5% by weight, preferably 0.5 to 2% by weight, more preferably 0. 5 to 1.5% by weight, more preferably 0.5 to 1.0% by weight can be mentioned.
本発明の口腔用組成物中に前記アミノ酸系アニオン界面活性剤以外に、当該分野において一般的に使用される界面活性剤を配合することを制限するものではない。しかし、本発明の口腔用組成物は、アミノ酸系アニオン界面活性剤を用いることにより、口内に適用した場合の刺激を低減しながらも、使用者が満足し得る起泡性を実現するものである。従って、本発明の口腔用組成物に含まれる前記アミノ酸系アニオン界面活性剤は、他の界面活性剤との総重量に対して50重量%以上、好ましくは80重量%以上、より好ましくは90重量%以上の割合で含まれていることが望ましい。また、本発明の口腔用組成物中に含まれる界面活性剤のうち、アニオン界面活性剤の総重量に対する前記アミノ酸系アニオン界面活性剤の割合が50重量%以上、好ましくは80重量%以上、より好ましくは90重量%以上の割合で含まれていることが望ましい。 The composition for oral cavity of the present invention is not limited to the surfactant generally used in the field other than the above-mentioned amino acid based anionic surfactant. However, the composition for oral cavity of the present invention achieves a satisfactory foamability to the user while reducing irritation when applied to the mouth by using an amino acid based anionic surfactant. . Therefore, the amino acid-based anionic surfactant contained in the composition for oral cavity of the present invention is 50% by weight or more, preferably 80% by weight or more, more preferably 90% by weight with respect to the total weight with other surfactants. It is desirable to be included in a proportion of% or more. Further, among the surfactants contained in the composition for oral cavity of the present invention, the ratio of the amino acid based anionic surfactant to the total weight of the anionic surfactant is 50% by weight or more, preferably 80% by weight or more, It is desirable that 90% by weight or more is contained.
(B)成分
本発明の口腔用組成物において(B)成分として、トウキ、シャクヤク、サリチル酸、サリチル酸の誘導体及びサリチル酸の塩からなる群より選択される少なくとも1種が使用される。
(B) Component In the composition for oral cavity of the present invention, as the component (B), at least one selected from the group consisting of toki, shakuyaku, salicylic acid, derivatives of salicylic acid and salts of salicylic acid is used.
トウキ(当帰)は、セリ科(Umbelliferae)のトウキAngelica acutiloba Kitagawa又はその他近縁植物の根で、通例、湯通ししたものであり、生薬(日本薬局方)として、婦人薬、冷え症用薬、保健強壮薬、精神神経用薬及び尿路疾患用薬などの処方に配合して用いられる。トウキについては、丸善製薬株式会社、三國株式会社、一丸ファルコス株式会社等から商業的に入手可能である。 Touki (Toki) is the root of the Tochii Angelica acutiloba Kitagawa or other related plants of the Umbelliferae (Umbelliferae), and is usually blanched, and as a herbal medicine (Japanese Pharmacopoeia), a gynecological drug, a medicine for cold, health It is used by combining it with prescriptions such as tonics, drugs for neuropsychiatric drugs and drugs for urinary tract diseases. Touki is commercially available from Maruzen Pharmaceutical Co., Ltd., Mikuni Co., Ltd., Ichimaru Falcos Co., Ltd., and the like.
シャクヤク(芍薬)は、ボタン科(Paeoniaceae)のシャクヤクPaeonia lactiflora Pallas又はその他近縁植物の根であり、生薬(日本薬局方)として主に鎮痛鎮痙薬(胃腸薬)、婦人薬、冷え症用薬、風邪薬などの用途に使用される。なお、シャクヤクは、生薬名(日本薬局方)でもあるとともに植物名でもある。シャクヤクについては、丸善製薬株式会社、三國株式会社、一丸ファルコス株式会社等から商業的に入手可能である。 A peony (peculiar) is the root of Paeonia lactiflora Pallas or other related plants of the family Peaoniaceae, and mainly as an herbal medicine (Japanese Pharmacopoeia) an analgesic and antispasmodic drug (a gastrointestinal drug), a gynecological drug, a medicine for chills, Used for cold medicine and other uses. Peony is a herbal medicine name (Japanese Pharmacopoeia) and a plant name. The peony is commercially available from Maruzen Pharmaceutical Co., Ltd., Mikuni Co., Ltd., Ichimaru Falcos Co., Ltd., and the like.
サリチル酸は、C6H4(OH)COOHで表わされる化合物である。本発明においては、(B)成分としてサリチル酸の他に、サリチル酸の誘導体、サリチル酸の塩も同様に使用することができる。サリチル酸の誘導体としては、例えば、アセチルサリチル酸、スルホサリチル酸、サリチル酸メチル、サリチル酸エチル、サリチル酸グリコール、サリチル酸エチレングリコール、サリチル酸ジプロピレングリコール、サリチル酸チタン、サリチル酸2−エチルヘキシル、サリチル酸ホモメンチル、サリチル酸フェニル、サリチル酸アミド等が挙げられる。また、サリチル酸の塩としては、例えば、ナトリウム、カリウム等のアルカリ金属塩;マグネシウム等のアルカリ土類金属塩が挙げられる。本発明において使用されるサリチル酸の塩として具体的には、サリチル酸ナトリウム、サリチル酸カリウム、サリチル酸カルシウム、ジサリチル酸マグネシウム等が例示される。これらの中でも、サリチル酸、サリチル酸の塩、サリチル酸メチル、サリチル酸エチルが好適なものとして挙げられ、これらの中で、サリチル酸メチルが更に好適なものとして挙げられる。サリチル酸メチルについては、例えば、東京化成工業株式会社、フィルメニッヒ株式会社、JQC株式会社等から商業的に入手可能である。 Salicylic acid is a compound represented by C 6 H 4 (OH) COOH. In the present invention, in addition to salicylic acid as the component (B), derivatives of salicylic acid and salts of salicylic acid can be used as well. As derivatives of salicylic acid, for example, acetylsalicylic acid, sulfosalicylic acid, methyl salicylate, ethyl salicylate, glycol salicylate, ethylene glycol salicylate, ethylene glycol salicylate, dipropylene glycol salicylate, titanium salicylate, 2-ethylhexyl salicylate, homomentyl salicylate, phenyl salicylate, salicylic acid amide etc. It can be mentioned. Moreover, as a salt of salicylic acid, for example, alkali metal salts such as sodium and potassium; alkaline earth metal salts such as magnesium and the like can be mentioned. Specific examples of the salt of salicylic acid used in the present invention include sodium salicylate, potassium salicylate, calcium salicylate, magnesium disalicylate and the like. Among these, salicylic acid, salts of salicylic acid, methyl salicylate and ethyl salicylate are mentioned as suitable ones, and among these, methyl salicylate is mentioned as further preferable one. Methyl salicylate is commercially available, for example, from Tokyo Chemical Industry Co., Ltd., Filmenich Co., Ltd., JQC Co., etc.
また、本発明においては(B)成分として、トウキ、シャクヤク、サリチル酸、サリチル酸の誘導体又はサリチル酸塩を1種単独で用いてもよく、2種以上を併用してもよい。2種以上を併用する場合の具体的な組合せは特に限定されないが、例えば、トウキとシャクヤク;トウキとサリチル酸メチル;シャクヤクとサリチル酸メチル;トウキ、シャクヤク及びサリチル酸メチル等が挙げられる。特に、泡立ちを高める効果が高いという点から、トウキとサリチル酸メチルの組み合わせ、又はトウキ、シャクヤク及びサリチル酸メチルの組み合わせが好ましい。また、2種以上を併用する場合の比率は特に限定されず、適宜調整すればよいが、例えば各化合物を等量で用いることができる。 In the present invention, as the component (B), one or two or more species of touki, peony, salicylic acid, a derivative of salicylic acid or salicylate may be used alone or in combination. Specific combinations in the case of using two or more kinds in combination are not particularly limited, and examples thereof include touki and peony; touki and methyl salicylate; peony and methyl salicylate; touki, peony and methyl salicylate and the like. In particular, from the viewpoint of a high effect of enhancing foaming, a combination of touki and methyl salicylate or a combination of touki, peony and methyl salicylate is preferred. Moreover, the ratio in the case of using 2 or more types together is not specifically limited, Although it may adjust suitably, for example, each compound can be used by equivalent amount.
本発明の口腔用組成物は、前記(A)成分100重量部に対する前記(B)成分を0.1〜500重量部の割合で含有する。また、(B)成分の好ましい配合割合として1〜200重量部、より好ましくは2〜200重量部、更に好ましくは10〜200重量部が挙げられる。例えば、(B)成分としてトウキを使用する場合の好ましい配合割合は、(A)成分100重量部に対して1〜200重量部、より好ましくは2〜200重量部、更に好ましくは10〜200重量部が挙げられる。また、(B)成分としてシャクヤクを使用する場合の好ましい配合割合は、(A)成分100重量部に対して1〜200重量部、より好ましくは2〜200重量部、更に好ましくは6.6〜200重量部が挙げられる。更に、サリチル酸、サリチル酸の誘導体及びサリチル酸の塩からなる群より選択される少なくとも1種を用いる場合の好ましい配合割合は、(A)成分100重量部に対して1〜200重量部、より好ましくは2〜200重量部、更に好ましくは10〜200重量部が挙げられる。 The composition for oral cavity of the present invention contains the component (B) in a ratio of 0.1 to 500 parts by weight with respect to 100 parts by weight of the component (A). Moreover, as a preferable mixture ratio of (B) component, 1 to 200 parts by weight, more preferably 2 to 200 parts by weight, and still more preferably 10 to 200 parts by weight can be mentioned. For example, in the case of using Touki as the component (B), the preferable blending ratio is 1 to 200 parts by weight, more preferably 2 to 200 parts by weight, still more preferably 10 to 200 parts by weight with respect to 100 parts by weight of the component (A). Department is listed. In addition, a preferable blending ratio in the case of using peony as the component (B) is 1 to 200 parts by weight, more preferably 2 to 200 parts by weight, still more preferably 6.6 to 100 parts by weight of the component (A). 200 parts by weight can be mentioned. Furthermore, when using at least one selected from the group consisting of salicylic acid, derivatives of salicylic acid and salts of salicylic acid, a preferable blending ratio is 1 to 200 parts by weight, more preferably 2 with respect to 100 parts by weight of the component (A). -200 parts by weight, more preferably 10-200 parts by weight can be mentioned.
このような割合で(B)成分を配合することにより、(A)成分の起泡力を向上させることができ、口内での豊かな泡立ちを実現し、使用者に優れた使用感、清掃感を与えることができる。また、(B)成分として2種以上を併用する場合には、(B)成分の総量として前記配合割合を満たすように調整すればよい。 By blending the component (B) at such a ratio, the foaming power of the component (A) can be improved, and rich foaming in the mouth can be realized, and the use feeling and cleaning feeling superior to the user can be realized. Can be given. Moreover, what is necessary is just to adjust so that the said compounding ratio may be satisfy | filled as a total amount of (B) component, when using 2 or more types together as (B) component.
2.好ましい態様
本発明の口腔用組成物の剤型は、粉末状、液状、ゲル状、顆粒状、錠剤状のいずれであってもよく、口内の清掃、清涼感の付与、殺菌、口臭防止等を目的として口腔内に適用される限り、従来公知の態様から適宜選択することができる。本発明の口腔用組成物の剤型として具体的には、粉歯磨剤、練歯磨剤、ジェル歯磨剤及び液体歯磨剤等の歯磨剤、ならびに洗口剤等が例示される。また、液状の剤型については、原液のまま使用するタイプであってもよく、濃縮タイプであって使用時に希釈して用いるタイプであってもよい。本発明の口腔用組成物の剤型を歯磨剤又は洗口剤とすることにより、口内に適用した場合に口腔粘膜に対する刺激の低減、優れた起泡性をより一層顕著に実感することができることから、これらが本発明における好適な剤型として挙げられる。特に、練歯磨剤及びジェル歯磨剤においては、起泡性と洗浄効果感の相関が強く、起泡性が向上した場合、その差異を敏感に実感することができるため、練歯磨剤及びジェル歯磨剤は、本発明における好適な剤型として挙げられる。
2. Preferred embodiment The dosage form of the composition for oral cavity of the present invention may be any of powder, liquid, gel, granules, and tablets, and it is possible to clean the mouth, give a refreshing feeling, sterilize, prevent bad breath, etc. As long as it is applied to the intraoral as an object, it can be appropriately selected from conventionally known modes. Specific examples of the dosage form of the composition for oral cavity of the present invention include toothpastes such as powder toothpaste, toothpaste, gel toothpaste and liquid toothpaste, and mouthwash. In addition, the liquid dosage form may be a type that is used as it is as a stock solution, or may be a concentration type that is used by diluting at the time of use. By applying a dosage form of the composition for oral cavity of the present invention to a dentifrice or a mouthwash, it is possible to realize the reduction of irritation to the oral mucosa and the excellent foamability more remarkably when applied to the mouth From these, these are mentioned as suitable dosage forms in the present invention. In particular, in the toothpaste and gel dentifrice, the correlation between the foamability and the feeling of cleaning is strong, and when the foamability is improved, the difference can be perceived sensitively, so toothpaste and gel toothpaste The agent is mentioned as a suitable dosage form in the present invention.
上記(A)成分及び(B)成分を含む本発明の口腔用組成物には、本発明の効果を損なわない範囲で、口腔用組成物に通常配合され得る各種、研磨剤、発泡剤、増粘剤、香料、甘味剤、湿潤剤、抗酸化剤、pH調整剤、着色剤、防腐剤等の添加剤や、薬理活性成分、溶剤等を添加し、従来公知の手法に従って所望の剤型に調製することができる。 In the composition for the oral cavity of the present invention containing the above components (A) and (B), various kinds of abrasives, foaming agents, and the like which can be usually blended in the composition for oral cavity within the range not impairing the effects of the present invention. Add additives such as thickener, flavor, sweetening agent, wetting agent, antioxidant, pH adjuster, coloring agent, preservative, etc., pharmacologically active ingredient, solvent etc. It can be prepared.
研磨剤としては、口腔用組成物に一般的に使用される種々の研磨剤を配合することができ、特に限定されないが、例えば、第1リン酸カルシウム、第2リン酸カルシウム・2水和物及び無水和物、第3リン酸カルシウム、炭酸カルシウム、ピロリン酸カルシウム、水酸化アルミニウム、アルミナ、シリカゲル、無水ケイ酸、ケイ酸アルミニウム、沈降性シリカ、不溶性メタリン酸ナトリウム、第3リン酸マグネシウム、炭酸マグネシウム、硫酸カルシウム、ポリメタクリル酸メチル、ベントナイト、ケイ酸ジルコニウム、チタニウム結合ケイ酸塩等が挙げられる。 As the polishing agent, various polishing agents generally used in oral compositions can be blended, and are not particularly limited. For example, primary calcium phosphate, secondary calcium phosphate dihydrate and anhydrate Calcium phosphate, calcium carbonate, calcium pyrophosphate, aluminum hydroxide, alumina, silica gel, anhydrous silica, aluminum silicate, precipitated silica, insoluble sodium metaphosphate, magnesium phosphate, magnesium carbonate, calcium sulfate, polymethacrylic acid And methyl acid, bentonite, zirconium silicate, titanium-bonded silicate and the like.
発泡剤としては、本発明の(A)成分であるアミノ酸系アニオン界面活性剤以外のアニオン界面活性剤やノニオン界面活性剤、カチオン界面活性剤、両性界面活性剤を配合することができる。より具体的には、アニオン界面活性剤としては、例えば、ドデシルベンゼンスルホン酸ナトリウム、水素添加ココナッツ脂肪酸モノグリセリドモノ硫酸ナトリウム、α−オレフィンスルホン酸ナトリウム等が挙げられる。ノニオン界面活性剤としては、例えば、ショ糖脂肪酸エステル、マルトース脂肪酸エステル、マルチトール脂肪酸エステル、ラクトール脂肪酸エステル、ソルビタン脂肪酸エステル、ポリオキシエチレンソルビタンモノステアレート、ポリオキシエチレン高級アルコールエーテル、ポリオキシエチレン硬化ヒマシ油、ポリオキシエチレンポリオキシプロピレン共重合体、ポリオキシエチレンポリオキシプロピレン脂肪酸エステル、ポリグリセリン脂肪酸エステル等が挙げられる。カチオン界面活性剤としては、例えば、塩化ラウリルトリメチルアンモニウム、塩化ステアリルトリメチルアンモニウム、塩化ベンゼトニウム、塩化セチルピリジニウム、塩化ベンザルコニウム、塩化ステアリルジメチルベンジルアンモニウム等が挙げられる。両性界面活性剤としては、例えば、ヤシ油脂肪酸アミドプロピルベタイン、ラウリルジメチルアミノ酢酸ベタイン、ラウリルジメチルアミンオキシド、2-アルキル−N−カルボキシメチル−N−ヒドロキシエチルイミダゾリウムベタイン、N−ラウリルジアミノエチルグリシン、N−ミリスチルジアミノエチルグリシン、N−アルキル−1−ヒドロキシエチルイミダゾリンベタインナトリウム等が挙げられる。本発明において、アミノ酸系アニオン界面活性剤以外の界面活性剤の配合割合は、組成物全体に対して2.5重量%以下、好ましくは2重量%以下であることが望ましい。 As the foaming agent, an anionic surfactant other than the amino acid based anionic surfactant, which is the component (A) of the present invention, a nonionic surfactant, a cationic surfactant, or an amphoteric surfactant can be blended. More specifically, examples of the anionic surfactant include sodium dodecylbenzene sulfonate, hydrogenated coconut fatty acid monoglyceride sodium monosulfate, sodium α-olefin sulfonate and the like. As a nonionic surfactant, for example, sucrose fatty acid ester, maltose fatty acid ester, maltitol fatty acid ester, lactol fatty acid ester, sorbitan fatty acid ester, polyoxyethylene sorbitan monostearate, polyoxyethylene higher alcohol ether, polyoxyethylene cured Castor oil, polyoxyethylene polyoxypropylene copolymer, polyoxyethylene polyoxypropylene fatty acid ester, polyglycerin fatty acid ester and the like can be mentioned. Examples of the cationic surfactant include lauryl trimethyl ammonium chloride, stearyl trimethyl ammonium chloride, benzethonium chloride, cetyl pyridinium chloride, benzalkonium chloride, stearyl dimethyl benzyl ammonium chloride and the like. As an amphoteric surfactant, for example, coconut oil fatty acid amidopropyl betaine, lauryl dimethylaminoacetic acid betaine, lauryl dimethyl amine oxide, 2-alkyl-N-carboxymethyl-N-hydroxyethyl imidazolium betaine, N-lauryl diaminoethyl glycine , N-myristyldiaminoethylglycine, N-alkyl-1-hydroxyethyl imidazoline betaine sodium and the like. In the present invention, the blending ratio of surfactants other than the amino acid based anionic surfactant is desirably 2.5% by weight or less, preferably 2% by weight or less, based on the whole composition.
増粘剤としては、キサンタンガム、アルギン酸ナトリウム、ポリビニルアルコール、ヒドロキシエチルセルロース、ポリアクリル酸ナトリウム、カラギナン、カルボキシメチルセルロースナトリウム、ポリビニルピロリドン等が挙げられる。 As the thickener, xanthan gum, sodium alginate, polyvinyl alcohol, hydroxyethyl cellulose, sodium polyacrylate, carrageenan, sodium carboxymethylcellulose, polyvinyl pyrrolidone and the like can be mentioned.
香料としては、l−メントール、l−カルボン、シンナミックアルデヒド、オレンジオイル、アネトール、1,8−シネオール、メチルサリシレート、オイゲノール、チモール、リナロール、リモネン、メントン、メンチルアセテート、シトラール、カンファー、ボルネオール、ピネン、スピラントール、エチルアセテート、エチルブチレート、イソアミルアセテート、ヘキサナール、ヘキセナール、メチルアンスラニレート、エチルメチルフェニルグリシデート、ベンズアルデヒド、バニリン、エチルバニリン、フラネオール、マルトール、エチルマルトール、ガンマ/デルタデカラクトン、ガンマ/デルタウンデカラクトン、N−エチル−p−メンタン−3−カルボキサミド、メンチルラクテート、エチレングリコール−l−メンチルカーボネート等の香料成分;ペパーミント油、スペアミント油、ユーカリ油、クローブ油、タイム油、セージ油、カルダモン油、ローズマリー油、マジョラム油、レモン油、ナツメグ油、ラベンダー油、パラクレス油等の天然精油;アップル、バナナ、ストロベリー、ブルーベリー、メロン、ピーチ、パイナップル、グレープ、マスカット、ワイン、チェリー、スカッシュ、コーヒー、ブランデー、ヨーグルト等の調合フレーバーが挙げられる。 As a flavor, l-menthol, l-carvone, cinnamic aldehyde, orange oil, anethole, 1,8-cineole, methyl salicylate, eugenol, thymol, linalool, limonene, menthone, menthyl acetate, citral, camphor, borneol, pinene Spiranthol, ethyl acetate, ethyl butyrate, isoamyl acetate, hexanal, hexenal, methyl anthranilate, ethyl methyl phenyl glycidate, benzaldehyde, vanillin, ethyl vanillin, furanoleol, maltol, ethyl maltol, gamma / delta decalactone, gamma / Deltown Decalactone, N-ethyl-p-menthane-3-carboxamide, menthyl lactate, ethylene glycol-l-menthylca Flavor components such as Bonate; Peppermint oil, spearmint oil, eucalyptus oil, clove oil, thyme oil, sage oil, cardamom oil, rosemary oil, marjoram oil, lemon oil, nutmeg oil, lavender oil, paracres oil etc. Natural essential oils; Blended flavors such as apple, banana, strawberry, blueberry, melon, peach, pineapple, grape, muscat, wine, cherry, squash, coffee, brandy, yogurt etc. may be mentioned.
甘味剤としては、サッカリンナトリウム、アセスルファームK、ステビオサイド、ネオヘスポリジルジヒドロカルコン、グリチルリチン、ペリラルチン、タウマチン、アスパルチルフェニルアラニンメチルエステル、p−メトキシシンナミックアルデヒド、アスパルテーム、キシリトール、エリスリトール等が挙げられる。 As the sweetening agent, saccharin sodium, acesulfame K, stevioside, neohespolysil dihydrochalcone, glycyrrhizin, perilaltin, thaumatin, aspartylphenylalanine methyl ester, p-methoxycinnamic aldehyde, aspartame, xylitol, erythritol and the like can be mentioned.
湿潤剤としては、ソルビット、グリセリン、濃グリセリン、エチレングリコール、プロピレングリコール、1,3−ブチレングリコール、ポリエチレングリコール、ポリプロピレングリコール等が挙げられる。 The wetting agent may, for example, be Sorbit, glycerin, concentrated glycerin, ethylene glycol, propylene glycol, 1,3-butylene glycol, polyethylene glycol, polypropylene glycol or the like.
抗酸化剤としては、ローズマリー抽出物、ステビア抽出物、ヒマワリ種子抽出物、没食子酸プロピル、ジブチルヒドロキシトルエン、ブチルヒドロキシアニソール、L−システイン塩酸塩、フィチン酸、ハイドロキノン及びその配糖体、ノルジヒドログアヤレチン酸、グアヤク脂、ポリフェノール、トコフェロール酢酸エステル、マツエキス、アスコルビン酸等が挙げられる。 As an antioxidant, rosemary extract, stevia extract, sunflower seed extract, propyl gallate, dibutylhydroxytoluene, butylhydroxyanisole, L-cysteine hydrochloride, phytic acid, hydroquinone and its glycoside, nor dihydrochloride Guararetic acid, guaiac fat, polyphenol, tocopherol acetate, pine extract, ascorbic acid and the like can be mentioned.
pH調整剤としては、フタル酸、リン酸、クエン酸、コハク酸、酢酸、フマル酸、リンゴ酸、炭酸やそれらのカリウム塩、ナトリウム塩又はアンモニウム塩、水酸化ナトリウムなどが挙げられる。本発明の口腔用組成物のpHは、口腔内及び人体に安全性上問題ない範囲であれば特に限定されるものではないが、例えば口腔用組成物30gを25℃70mLの水に溶解させた場合のpHの範囲としてpH4〜9が挙げられる。本発明の口腔用組成物のpHは、必要に応じて前記pH調整剤を使用して当該範囲に調整され得る。 Examples of pH adjusters include phthalic acid, phosphoric acid, citric acid, succinic acid, acetic acid, fumaric acid, malic acid, carbonic acid and their potassium salts, sodium salts or ammonium salts, sodium hydroxide and the like. The pH of the composition for oral cavity of the present invention is not particularly limited as long as there is no problem with safety in the oral cavity and the human body. For example, 30 g of the composition for oral cavity was dissolved in 70 mL of water at 25 ° C. The pH range of the case includes pH 4-9. The pH of the composition for oral cavity of the present invention can be adjusted to the relevant range using the above-mentioned pH adjuster, if necessary.
着色剤としては、例えば、赤色2号、赤色3号、赤色225号、赤色226号、黄色4号、黄色5号、黄色205号、青色1号、青色2号、青色201号、青色204号、緑色3号、雲母チタン、酸化チタン等が挙げられる。 As a coloring agent, for example, Red No. 2, Red No. 3, Red No. 225, Red No. 226, Yellow No. 4, Yellow No. 5, Yellow No. 205, Yellow No. 1, Blue No. 1, Blue No. 2, Blue No. 201, Blue No. 204 Green, No. 3, mica titanium, titanium oxide and the like.
防腐剤としては、例えば安息香酸ナトリウム、メチルパラベン、エチルパラベン、プロピルパラベン、ブチルパラベン等のパラベン類、塩化セチルピリジニウム、塩酸アルキルジアミノエチルグリシン、ソルビン酸カリウム等が挙げられる。 Examples of the preservative include parabens such as sodium benzoate, methyl paraben, ethyl paraben, propyl paraben, butyl paraben, cetyl pyridinium chloride, alkyldiaminoethyl glycine hydrochloride, potassium sorbate and the like.
薬理活性成分としては、例えばクロロヘキシジン、トリクロサン、イソプロピルメチルフェノール、塩化セチルピリジニウム、グルコン酸亜鉛、クエン酸亜鉛等の殺菌又は抗菌剤;トラネキサム酸、グリチルリチン酸ジカリウム塩等の抗炎症剤;アラントイン、アラントインクロルヒドロキシアルミニウム、アスコルビン酸、塩化リゾチーム、グリチルリチン酸及びその塩類、塩化ナトリウム、乳酸アルミニウム等の収斂剤;デキストラナーゼ、アミラーゼ、プロテアーゼ、ムタナーゼ、リゾチーム等の酵素;塩化ストロンチウム、硝酸カリウム等の知覚過敏抑制剤などが挙げられ、これらを薬剤学的に許容できる範囲で使用することができる。 As pharmacologically active ingredients, for example, bactericidal or antibacterial agents such as chlorhexidine, triclosan, isopropylmethylphenol, cetyl pyridinium chloride, zinc gluconate, zinc citrate and the like; anti-inflammatory agents such as tranexamic acid, glycyrrhizinic acid dipotassium salt; allantoin, allantoin chlorate Hydroxyaluminum, ascorbic acid, lysozyme chloride, glycyrrhizinic acid and salts thereof, astringent agents such as sodium chloride and aluminum lactate; enzymes such as dextranase, amylase, protease, mutanase, lysozyme; hypersensitivity inhibitors such as strontium chloride and potassium nitrate And the like, and these can be used in a pharmaceutically acceptable range.
溶剤としては、エタノールやイソプロピルアルコール等を使用することができる。 As the solvent, ethanol, isopropyl alcohol or the like can be used.
本発明の口腔用組成物中の任意成分の含有量としては、配合される各成分の量、担体、添加剤の種類等に応じて適宜設定され得るが、総量として1〜80重量%が挙げられる。 The content of optional components in the composition for oral cavity of the present invention may be appropriately set according to the amount of each component to be blended, the type of carrier, additive, etc., but 1 to 80% by weight as a total Be
また、本発明の口腔用組成物は、薬理学的に許容される従来公知の担体を含んでいてもよい。このような担体としては、例えば水(イオン交換水、蒸留水、精製水等)、生理食塩水等の水性担体;高級脂肪酸、植物油、動物油、シリコーン油類、金属石鹸等の油性担体が挙げられる。本発明において、これらの担体の含有量は、口腔用組成物において上記(A)及び(B)成分と、その他の任意成分以外の残部に相当するように調整される。 The oral composition of the present invention may also contain pharmacologically acceptable conventionally known carriers. Examples of such carriers include aqueous carriers such as water (ion-exchanged water, distilled water, purified water etc.), physiological saline, etc .; and oily carriers such as higher fatty acids, vegetable oils, animal oils, silicone oils, metal soaps, etc. . In the present invention, the content of these carriers is adjusted to correspond to the components (A) and (B) and the balance other than the other optional components in the composition for oral cavity.
本発明の口腔用組成物の適用量は特に限定されず、用途に応じて適宜調整され得るが、例えば、練歯磨剤の場合には、0.2〜1gが挙げられ、液体歯磨剤や洗口剤の場合には5〜20mLが挙げられる。 The application amount of the composition for oral cavity of the present invention is not particularly limited and may be appropriately adjusted depending on the application, but in the case of a toothpaste, for example, 0.2 to 1 g may be mentioned. In the case of mouth drops, 5 to 20 mL can be mentioned.
以下に実施例等を示し、本発明を具体的に説明する。但し、本発明はこれらに限定されない。 The present invention will be specifically described by way of examples and the like below. However, the present invention is not limited to these.
[起泡力の評価]
下表1〜10に示される歯磨剤を、原料を室温(約25℃)下において脱気混合することにより調製した。より具体的には、(A)成分、精製水、濃グリセリン、ソルビット液及び無水ケイ酸を10分間攪拌混合した後、別途混合しておいた(B)成分、エタノール及びポリオキシエチレン硬化ヒマシ油を加えて10分間撹拌し、最後にカルボキシメチルセルロースナトリウム及びポリアクリル酸ナトリウムを加えて更に15分撹拌し脱気させた。
[Evaluation of foaming power]
The dentifrices shown in Tables 1 to 10 below were prepared by degassing the raw materials at room temperature (about 25 ° C.). More specifically, component (A), purified water, concentrated glycerine, sorbit solution and silicic anhydride are stirred and mixed for 10 minutes and then separately mixed with component (B), ethanol and polyoxyethylene hydrogenated castor oil. Was added and stirred for 10 minutes, and finally sodium carboxymethylcellulose and sodium polyacrylate were added and stirred for another 15 minutes for degassing.
得られた歯磨剤15gに対して精製水(25℃)75gを加え、よく懸濁し試料溶液とした。試料溶液60mLをメスシリンダーにとり、ホモジェナイザー(System POLYTRON PT−K)の攪拌翼を液面から約3分の2の位置に設置した。室温(約25℃)において回転速度約5000rpmで10秒間回転させた後、攪拌翼が停止して泡沫が安定したとき(約5秒後)に、泡部分の最上部のメスシリンダーの目盛り(mL)を測定した。下記数式1に示されるように泡部分と液部分(60mL)の差を発泡量とした。 To 15 g of the obtained dentifrice, 75 g of purified water (25 ° C.) was added, and well suspended to prepare a sample solution. 60 mL of the sample solution was placed in a measuring cylinder, and the stirring blade of the homogenizer (System POLYTRON PT-K) was placed at a position about two thirds from the liquid surface. After rotating for 10 seconds at a rotation speed of about 5000 rpm at room temperature (about 25 ° C.), when the stirring blade is stopped and the foam is stabilized (after about 5 seconds), the graduation (mL Was measured. The difference between the foam portion and the liquid portion (60 mL) was taken as the foam amount as shown in the following Formula 1.
<数式1>
発泡量=泡部分の最上部の目盛−液部分(60mL)
Formula 1
Foaming amount = scale on top of foam part-liquid part (60 mL)
結果を下表1〜10に示す。 The results are shown in Tables 1 to 10 below.
表1に示されるように、アミノ酸系アニオン界面活性剤としてラウロイルメチルタウリンナトリウムを用いた場合、当該界面活性剤と、シラカバ、オウバク、コリアンダー又はユーカリといった本発明の(B)成分以外の生薬や精油とを組み合わせた参考比較例1〜4の歯磨剤の発泡量は、ラウロイルメチルタウリンナトリウムを単独で含有する歯磨剤(比較例1)に比べて低下し、満足な発泡量が得られないことが示された。 As shown in Table 1, when sodium lauroyl methyl taurine is used as the amino acid-based anionic surfactant, the surfactant and the herbal medicine or essential oil other than the component (B) of the present invention, such as birch, oat, coriander or eucalyptus The amount of foaming of the dentifrices of Reference Comparative Examples 1 to 4 combined with the above is lower than that of dentifrices containing sodium lauroyl methyl taurine alone (Comparative Example 1), and a satisfactory amount of foaming can not be obtained. Indicated.
表2〜4に示されるように、(A)成分としてラウロイルメチルタウリンナトリウムを用い、(B)成分としてサリチル酸メチル、トウキ又はシャクヤクを組合せると、優れた起泡力が得られることが示された(実施1〜23)。 As shown in Tables 2 to 4, using sodium lauroyl methyl taurine as the component (A) and combining methyl salicylate, toki or peony as the component (B), it was shown that excellent foamability can be obtained. (Implementation 1-23).
また、(A)成分としてラウロイルメチルタウリンナトリウムを0.5重量%含有する場合、(B)成分であるサリチル酸メチルの配合量を(A)成分100重量部に対して10〜200重量部とすることにより、(A)成分単独で含有する場合(比較例1)に比べて発泡増加量を115%以上とすることができ、より一層優れた起泡力を付与できることが示された(実施例1〜4)。また、(B)成分としてトウキを用いる場合にも、トウキの配合量を(A)成分100重量部に対して10〜200重量部とすることにより発泡増加量を115%以上とすることができた(実施例8〜11)。更に(B)成分としてシャクヤクを用いる場合には、シャクヤクの配合量を(A)成分100重量部に対して6.6〜200重量部とすることにより発泡増加量を115%以上とすることができ(実施例14〜18)、特に、シャクヤクの配合量を6.6〜50重量部とすると、更に優れた起泡力を付与できることが示された(実施例15〜18)。 When 0.5% by weight of sodium lauroyl methyl taurine is contained as component (A), the blending amount of methyl salicylate as component (B) is 10 to 200 parts by weight with respect to 100 parts by weight of component (A). As a result, it was shown that the amount of increase in foaming can be made to be 115% or more as compared with the case where the component (A) alone is contained (Comparative Example 1), and a further excellent foaming power can be provided (Example 1-4). Further, even when using Touki as the component (B), the foaming increase amount can be made 115% or more by setting the blending amount of the touki to 10 to 200 parts by weight with respect to 100 parts by weight of the component (A). (Examples 8 to 11). Furthermore, in the case of using peony as the component (B), the foaming increase amount can be made 115% or more by setting the blending amount of peony to 6.6 to 200 parts by weight with respect to 100 parts by weight of the component (A). It was shown that when the blending amount of peony is 6.6 to 50 parts by weight (Examples 14 to 18), the foamability can be further improved (Examples 15 to 18).
また、(B)成分としてサリチル酸メチル、トウキ、シャクヤクをそれぞれ組合せて用いた場合にも、同様に発泡量の増加が示された(実施例20〜23)。特に、サリチル酸メチル及びトウキを組み合わせた場合(実施例20)並びにサリチル酸メチル、トウキ及びシャクヤクを組合せた場合(実施例21)、より一層高い起泡力を付与できることが示された。 Moreover, when the salicylic acid methyl salicylate, touki, and peony were respectively used in combination as the component (B), an increase in the amount of foaming was similarly shown (Examples 20 to 23). In particular, it was shown that higher foaming power can be imparted when methyl salicylate and toki were combined (Example 20) and when methyl salicylate, touki and peony were combined (Example 21).
表5及び6より、(A)成分としてラウロイルメチルタウリンナトリウムを1重量%含有する場合、(B)成分のサリチル酸メチルの配合量を(A)成分100重量部に対して10〜200重量部とすることにより発泡増加量が114%以上となり、より優れた起泡力を付与できることが示された(実施例24〜27)。また、(B)成分としてトウキを用いる場合、(A)成分100重量部に対する配合量を10〜200重量部とすることによって、より一層優れた起泡力が付与されることが示された(実施例29〜32)。更に、(B)成分としてシャクヤクを用いる場合も、(A)成分100重量部に対する配合量を10〜200重量部とすることにより、更に発泡量の増加が認められた(実施例34〜37) From Tables 5 and 6, when 1% by weight of sodium lauroyl methyl taurine is contained as the component (A), the blending amount of methyl salicylate of the component (B) is 10 to 200 parts by weight with respect to 100 parts by weight of the component (A) As a result, it was shown that the amount of increase in foaming was 114% or more, and it was possible to impart more excellent foamability (Examples 24 to 27). Moreover, when using a touki as (B) component, it was shown that the still more outstanding foaming power is provided by the compounding quantity with respect to 100 weight part of (A) component being 10-200 weight part. Examples 29-32). Furthermore, even when using peony as the component (B), an increase in the amount of foaming was observed by setting the amount to 10 to 200 parts by weight with respect to 100 parts by weight of the component (A) (Examples 34 to 37)
表7及び8に示されるように、(A)成分としてラウロイルメチルタウリンナトリウムを2重量%含有する場合、(B)成分のサリチル酸メチルの配合量を(A)成分100重量部に対して10〜50重量部とすることによって、より一層優れた起泡力を付与することができた(実施例40〜42)。また、(B)成分としてトウキを用いる場合には、(A)成分100重量部に対する配合量を10〜50重量部とすることによって、更に高い起泡性が示された(実施例45〜47)。更に、(B)成分としてシャクヤクを用いる場合には、(A)成分100重量部に対する配合量を10〜200重量部とすることによってより高い起泡性が示された。(実施例49〜52)。なお、実施例44、48及び53については、発泡量の増加率がいずれも107%程度となっており、他の実施例に比べると比較的発泡増加量が小さいが、これらの歯磨剤を口内に適用し、歯ブラシを用いてブラッシングした場合に、適度な泡立ちの向上を実感することができ、実用上十分な起泡力が付与されたものである。 As shown in Tables 7 and 8, when 2 wt% of lauroyl methyl taurine sodium is contained as the component (A), the blending amount of methyl salicylate of the component (B) is 10 to 10 parts by weight of the component (A). By setting the amount to 50 parts by weight, it was possible to impart even more excellent foaming power (Examples 40 to 42). Moreover, when using Touki as a (B) component, the still higher foamability was shown by making the compounding quantity with respect to 100 weight part of (A) component into 10 to 50 weight part (Examples 45 to 47) ). Furthermore, in the case of using peony as the component (B), higher foamability was shown by setting the compounding amount to 10 to 200 parts by weight with respect to 100 parts by weight of the component (A). (Examples 49-52). In Examples 44, 48, and 53, the increase rate of the foam amount is about 107% in all cases, and the foam increase amount is relatively small as compared with the other examples. When applied to a brush and brushed using a toothbrush, it is possible to realize a moderate improvement in lathering, and a practically sufficient foaming power is imparted.
表9に示されるように、(A)成分としてラウロイルグルタミン酸ナトリウムを用いた場合にも、(A)成分としてラウロイルメチルタウリンナトリウムを用いた場合と同様に(B)成分と組合せることによって発泡量が増加し、優れた起泡力を付与できることが示された。 As shown in Table 9, even when sodium lauroyl glutamate is used as component (A), the amount of foaming is obtained by combining it with component (B) as in the case where sodium lauroyl methyl taurine is used as component (A). It was shown that can increase and give excellent foaming power.
表10に示されるように、(A)成分としてラウロイルサルコシンナトリウムを用いた場合にも、(A)成分としてラウロイルメチルタウリンナトリウムを用いた場合と同様に(B)成分と組合せることによって発泡量が増加し、優れた起泡力を付与できることが示された。 As shown in Table 10, even when sodium lauroyl sarcosine is used as component (A), the amount of foaming is obtained by combining it with component (B) as in the case where sodium lauroyl methyl taurine is used as component (A). It was shown that can increase and give excellent foaming power.
また、表1〜10の、実施例1〜65の歯磨剤を実際に口内に適用し、歯ブラシを用いてブラッシングしたところ、泡立ちの向上だけでなく、泡立ちの向上に相関して洗浄効果の向上を実感することができた。 In addition, when the dentifrices of Examples 1 to 65 in Tables 1 to 10 were actually applied in the mouth and brushed using a toothbrush, not only the improvement of foaming but also the improvement of cleaning effect in correlation with the improvement of foaming. I was able to feel
[処方例:練歯磨剤]
下記表11〜17に練歯磨剤の処方例を示す。練歯磨剤の調製は、(A)成分、精製水、濃グリセリン、ソルビット液、無水ケイ酸、グリチルリチン酸ジカリウム、アラントイン、マツエキス、クエン酸ナトリウム、クエン酸を10分間攪拌混合した後、別途混合しておいた(B)成分、エタノール、ポリオキシエチレン硬化ヒマシ油、トコフェロール酢酸エステル及びl−メントールを10分間撹拌し、最後にカルボキシメチルセルロースナトリウム及びポリアクリル酸ナトリウムを加えて更に15分撹拌し脱気させることにより行った。
[Formulation example: toothpaste]
Tables 11 to 17 below show formulation examples of toothpaste. The toothpaste is prepared by stirring and mixing the component (A), purified water, concentrated glycerin, sorbit solution, silicic anhydride, silicic anhydride, dipotassium glycyrrhizinate, allantoin, pine extract, sodium citrate and citric acid for 10 minutes and separately mixing Stirred (B) component, ethanol, polyoxyethylene hydrogenated castor oil, tocopherol acetate and l-menthol for 10 minutes, finally add sodium carboxymethylcellulose and sodium polyacrylate, and stir for additional 15 minutes for degassing It was done by
[処方例:液体歯磨剤、洗口剤]
下表18に液体歯磨剤又は洗口剤の処方例を示す。液体歯磨剤又は洗口剤は、(A)成分、精製水、濃グリセリン、ソルビット液、グリチルリチン酸ジカリウム、アラントイン、マツエキス、クエン酸ナトリウム及びクエン酸を10分間撹拌した後、別途混合しておいた(B)成分、エタノール、トコフェロール酢酸エステル、ポリオキシエチレン硬化ヒマシ油及びL−メントールと共に更に10分間撹拌することにより調製される。
[Example of formulation: liquid dentifrice, mouthwash]
Table 18 below shows formulation examples of liquid dentifrices or mouthrinses. Liquid dentifrice or mouthrint was mixed separately after stirring (A) component, purified water, concentrated glycerin, sorbit solution, dipotassium glycyrrhizinate, allantoin, pine extract, sodium citrate and citric acid for 10 minutes It is prepared by further stirring for 10 minutes with the component (B), ethanol, tocopherol acetate, polyoxyethylene hydrogenated castor oil and L-menthol.
以上のいずれの処方の口腔用組成物も口内への刺激が低減され、且つ満足な使用感、清掃感が得られる起泡力を有していた。 The oral composition of any of the above formulations has a foaming power that reduces the irritation to the mouth and provides a satisfactory feeling of use and a feeling of cleaning.
Claims (5)
前記(A)成分100重量部に対する前記(B)成分の含有量が50〜500重量部である、口腔用組成物(但し、ハイドロキシアパタイトを含む口腔用組成物を除く)。 (A) lauroyl sarcosine and / or a salt thereof, and (B) touki
An oral composition containing 50 to 500 parts by weight of the component (B) based on 100 parts by weight of the component (A) (except for oral compositions containing hydroxyapatite).
前記(A)成分100重量部に対する前記(B)成分の含有量が50〜500重量部である、口腔用組成物(但し、アルキル硫酸ナトリウムを含む口腔用組成物、並びに、(B)成分としてサリチル酸メチル含む場合には、エストラゴール、クレオソール,ジャスモン酸メチル,アンスラニ酸メチル、バイオレット油、デカラクトン、ウンデカラクトン、ダマスコン、ダマセノン、イオノン、及びイロンよりなる群から選択される少なくとも1種を含む口腔用組成物を除く)。 (A) lauroyl sarcosine and / or a salt thereof, and (B) at least one selected from the group consisting of salicylic acid, methyl salicylate, ethyl salicylate and salts of salicylic acid,
An oral composition containing 50 to 500 parts by weight of the component (B) relative to 100 parts by weight of the component (A) (but containing a sodium alkyl sulfate, and as the component (B) When containing methyl salicylate, it contains at least one member selected from the group consisting of estragol, creosol, methyl jasmonate, methyl anthranilate, violet oil, decalactone, undecalactone, damascone, damascenone, ionone, and yrone Excluding oral compositions).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012287944 | 2012-12-28 | ||
JP2012287944 | 2012-12-28 | ||
JP2013267437A JP6522877B2 (en) | 2012-12-28 | 2013-12-25 | Oral composition |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013267437A Division JP6522877B2 (en) | 2012-12-28 | 2013-12-25 | Oral composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019116510A true JP2019116510A (en) | 2019-07-18 |
JP7390678B2 JP7390678B2 (en) | 2023-12-04 |
Family
ID=51423097
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013267437A Active JP6522877B2 (en) | 2012-12-28 | 2013-12-25 | Oral composition |
JP2019084502A Active JP7390678B2 (en) | 2012-12-28 | 2019-04-25 | Oral composition |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013267437A Active JP6522877B2 (en) | 2012-12-28 | 2013-12-25 | Oral composition |
Country Status (1)
Country | Link |
---|---|
JP (2) | JP6522877B2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6279956B2 (en) * | 2014-03-31 | 2018-02-14 | ライオン株式会社 | Dentifrice composition |
WO2015151915A1 (en) * | 2014-03-31 | 2015-10-08 | ライオン株式会社 | Toothpaste composition |
JP6385120B2 (en) * | 2014-04-15 | 2018-09-05 | ライオン株式会社 | Dentifrice composition |
US10524989B2 (en) | 2014-12-26 | 2020-01-07 | Kao Corporation | Liquid composition for oral cavity contained in foam-discharging container |
JP6459781B2 (en) * | 2015-05-29 | 2019-01-30 | ライオン株式会社 | Oral composition |
CN111084741A (en) * | 2019-12-30 | 2020-05-01 | 柳州两面针股份有限公司 | Application of red peony root extract in preparation of oral care products |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4843869B1 (en) * | 1969-11-08 | 1973-12-21 | ||
JPS5775911A (en) * | 1980-10-30 | 1982-05-12 | Sunstar Inc | Dentifrice composition |
JP2000281551A (en) * | 1999-03-12 | 2000-10-10 | Pfizer Prod Inc | Composition for oral cavity |
JP2011126818A (en) * | 2009-12-18 | 2011-06-30 | Lion Corp | Dentifrice composition |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5913712A (en) * | 1982-07-14 | 1984-01-24 | Lion Corp | Composition for oral cavity application |
JPH0629168B2 (en) * | 1984-03-08 | 1994-04-20 | ライオン株式会社 | Toothpaste composition |
JP4843869B2 (en) | 2001-05-30 | 2011-12-21 | 王子製紙株式会社 | Anti-counterfeiting thread and anti-counterfeiting paper |
JP4496429B2 (en) * | 2004-03-05 | 2010-07-07 | ライオン株式会社 | Dentifrice composition and dentifrice product |
JP2005289917A (en) | 2004-04-01 | 2005-10-20 | Lion Corp | Dentifrice composition |
JP4286195B2 (en) * | 2004-08-25 | 2009-06-24 | 株式会社サンギ | Oral composition |
JP2008094772A (en) * | 2006-10-13 | 2008-04-24 | Lion Corp | Liquid composition for oral cavity |
JP2012144490A (en) * | 2011-01-13 | 2012-08-02 | Sunstar Inc | Composition for external application |
-
2013
- 2013-12-25 JP JP2013267437A patent/JP6522877B2/en active Active
-
2019
- 2019-04-25 JP JP2019084502A patent/JP7390678B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4843869B1 (en) * | 1969-11-08 | 1973-12-21 | ||
JPS5775911A (en) * | 1980-10-30 | 1982-05-12 | Sunstar Inc | Dentifrice composition |
JP2000281551A (en) * | 1999-03-12 | 2000-10-10 | Pfizer Prod Inc | Composition for oral cavity |
JP2011126818A (en) * | 2009-12-18 | 2011-06-30 | Lion Corp | Dentifrice composition |
Also Published As
Publication number | Publication date |
---|---|
JP7390678B2 (en) | 2023-12-04 |
JP2014141471A (en) | 2014-08-07 |
JP6522877B2 (en) | 2019-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7390678B2 (en) | Oral composition | |
KR20120086685A (en) | Dentifrice composition | |
JP2008303188A (en) | Candida biofilm eliminating agent | |
JP5397181B2 (en) | Oral spray composition and oral preparation | |
JP2019052110A (en) | Oral composition | |
JP2011098918A (en) | Dentifrice composition | |
JP2005289917A (en) | Dentifrice composition | |
JP5233399B2 (en) | Oral spray composition and oral preparation | |
WO2015099152A1 (en) | Oral composition | |
JP2005187329A (en) | Composition for oral cavity | |
JP6911845B2 (en) | Oral composition | |
JP2020083787A (en) | Composition for oral cavity | |
JP5691413B2 (en) | Nonionic drug-containing composition and product | |
JP2007070256A (en) | Dentifrice composition | |
JP6734090B2 (en) | Oral composition | |
JP2021031426A (en) | Polyhydric alcohol dentifrice composition | |
WO2019107340A1 (en) | Composition for oral use | |
JP2015086164A (en) | Liquid oral composition | |
JP6173735B2 (en) | Dentifrice composition | |
JP2012193153A (en) | Liquid or liquid-form oral composition and agent for inhibiting adherence of tongue coating | |
CN109689016B (en) | Liquid oral composition | |
JP6897676B2 (en) | Oral composition | |
CN116806140A (en) | Oral composition | |
JP2023183797A (en) | Oral composition | |
JP2024049467A (en) | Oral Composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190524 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200707 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200907 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210202 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210401 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210817 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211015 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220301 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220525 |
|
C116 | Written invitation by the chief administrative judge to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C116 Effective date: 20220607 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20220607 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231113 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7390678 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |